Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Loading history...
Latest & greatest articles for breast cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. BreastCancerScreening Strategies. Controversy persists about optimal mammography screening strategies.To evaluate screening outcomes, taking into account advances in mammography and treatment of breast cancer.Collaboration of 6 simulation models using national data on incidence, digital mammography performance, treatment effects, and other-cause mortality.United States.Average-risk U.S. female population (...) and subgroups with varying risk, breast density, or comorbidity.Eight strategies differing by age at which screening starts (40, 45, or 50 years) and screening interval (annual, biennial, and hybrid [annual for women in their 40s and biennial thereafter]). All strategies assumed 100% adherence and stopped at age 74 years.Benefits (breastcancer-specific mortality reduction, breastcancer deaths averted, life-years, and quality-adjusted life-years); number of mammograms used; harms (false-positive results
Screening for BreastCancer: U.S. Preventive Services Task Force Recommendation Statement. Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for breast cancer.The USPSTF reviewed the evidence on the following: effectiveness of breastcancerscreening in reducing breastcancer-specific and all-cause mortality, as well as the incidence of advanced breastcancer and treatment-related morbidity; harms of breastcancerscreening; test performance (...) characteristics of digital breast tomosynthesis as a primary screening strategy; and adjunctive screening in women with increased breast density. In addition, the USPSTF reviewed comparative decision models on optimal starting and stopping ages and intervals for screening mammography; how breast density, breastcancer risk, and comorbidity level affect the balance of benefit and harms of screening mammography; and the number of radiation-induced breastcancer cases and deaths associated with different
. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 2 or 3 1 and 4 colonography, computed tomographic/ or colonoscopy/ or endoscopy, gastrointestinal/ or sigmoidoscopy/ or ((occult blood.ti,ab. or occult blood/) and (feces/ or (faeces or fecal or faecal or colorectal).ti,ab.)) or (enema/ and barium sulfate/) mammography/ or mammogra*.ti,ab. (colonography or colonoscop* or fobt (...) and uncontrolled vocabularies and search software. Following are the search strategies used in Medline. Databases : Medline mass screening/ or multiphasic screening/ or (screen or screened or screening).ti,ab. or "early detection of cancer"/ (neoplasms/ or breastneoplasms/ or colorectal neoplasms/ or uterine cervical neoplasms/ or carcinoma, ductal, breast/ or "hereditary breast and ovarian cancer syndrome"/ or inflammatory breastneoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs
or MRI will detect additional breastcancer but will also result in a higher number of false-positive results. Data on DBT in women with dense breasts are limited, but in the short term, DBT also detects additional breastcancer. Most of the additional cancer detected by these methods are invasive tumors rather than ductal carcinoma in situ (DCIS). , A short-term increase in the number of cancer cases detected does not allow for the conclusion that adjunctive screening reduces treatment-related (...) and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Importance Breastcancer is the second-leading cause of cancer death among women in the United States. In 2015, an estimated 232,000 women were diagnosed with the disease and 40,000 women died of it. It is most frequently diagnosed among women aged 55 to 64 years, and the median age of death from breastcancer is 68 years. Benefit and Harms of Screening and Early Treatment The USPSTF found adequate
of a woman's lifetime. ACS selected the Duke University Evidence Synthesis Group to conduct an independent systematic evidence review after a response to a request for proposals, and commissioned the BreastCancer Surveillance Consortium (BCSC) to update previously published analyses related to the screening interval and outcomes. The ACS Surveillance and Health Services Research Program provided supplementary data on disease burden using data from the Surveillance, Epidemiology, and End Results (SEER (...) Screening for BreastCancer in Women at Average Risk* Screening for BreastCancer in Women at Average Risk | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed
BreastCancerScreening in Low- and Middle-Income Countries: A Perspective From Malawi 28717676 2018 11 13 2378-9506 2 1 2016 Feb Journal of global oncology J Glob Oncol BreastCancerScreening in Low- and Middle-Income Countries: A Perspective From Malawi. 4-8 10.1200/JGO.2015.000430 Gutnik Lily A LA , Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY; , , , and , UNC-Project Malawi; , Malawi Ministry of Health; and , Kamuzu Central Hospital, Lilongwe; and , University (...) of Malawi College of Medicine, Blantyre, Malawi; , Gillings School of Global Public Health; , , and , Lineberger Comprehensive Cancer Center; and , Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC. Matanje-Mwagomba Beatrice B , Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY; , , , and , UNC-Project Malawi; , Malawi Ministry of Health; and , Kamuzu Central Hospital, Lilongwe; and , University of Malawi College
Digital breast tomosynthesis for breastcancer diagnosis and screening Digital breast tomosynthesis for breastcancer diagnosis and screening Digital breast tomosynthesis for breastcancer diagnosis and screening HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Digital breast tomosynthesis for breastcancer diagnosis and screening (...) . Lansdale: HAYES, Inc.. Directory Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH BreastNeoplasms; Humans; Mammography; Public Health; Tomography, X-Ray Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo
. Citation IQWiG. Einladungsschreiben und merkblatt zum mammographie-screening. [Invitation and fact sheet for breastcancerscreening] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 288. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH BreastNeoplasms; Early Detection of Cancers; Mass Screening Language Published German Country of organisation Germany English summary There is no English language summary available (...) [Invitation and fact sheet for breastcancerscreening] Einladungsschreiben und merkblatt zum mammographie-screening [Invitation and fact sheet for breastcancerscreening] Einladungsschreiben und merkblatt zum mammographie-screening [Invitation and fact sheet for breastcancerscreening] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database
BreastCancerScreening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. Breastcancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breastcancer morbidity and mortality.To update the American Cancer Society (ACS) 2003 breastcancerscreening guideline for women at average risk for breast cancer.The ACS commissioned a systematic evidence review of the breastcancerscreening literature (...) to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms.Screening mammography in women aged 40 to 69 years is associated with a reduction in breastcancer deaths across a range of study designs, and inferential evidence supports breastcancerscreening for women 70
Breast-CancerScreening - Viewpoint of the IARC Working Group. 26444742 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Breast-CancerScreening--Viewpoint of the IARC Working Group. 1479 10.1056/NEJMc1508733 Lauby-Secretan Béatrice B Loomis Dana D Straif Kurt K eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2015 Jun 11;372(24):2353-8 26039523 N Engl J Med. 2015 Oct 8;373(15):1478 26444743 N Engl J Med (...) . 2015 Oct 8;373(15):1478-9 26444744 N Engl J Med. 2015 Oct 8;373(15):1479 26444745 BreastNeoplasms diagnosis Breast Self-Examination Early Detection of Cancer Female Humans Mammography Practice Guidelines as Topic 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444742 10.1056/NEJMc1508733 10.1056/NEJMc1508733#SA4
Breast-CancerScreening - Viewpoint of the IARC Working Group. 26444743 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Breast-CancerScreening--Viewpoint of the IARC Working Group. 1478 10.1056/NEJMc1508733 Jørgensen Karsten J KJ Bewley Susan S eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2015 Jun 11;372(24):2353-8 26039523 N Engl J Med. 2015 Oct 8;373(15):1479 26444742 BreastNeoplasms diagnosis (...) Breast Self-Examination Early Detection of Cancer Female Humans Mammography Practice Guidelines as Topic 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444743 10.1056/NEJMc1508733 10.1056/NEJMc1508733#SA1
Breast-CancerScreening - Viewpoint of the IARC Working Group. 26444744 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Breast-CancerScreening--Viewpoint of the IARC Working Group. 1478-9 10.1056/NEJMc1508733 Jatoi Ismail I eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2015 Jun 11;372(24):2353-8 26039523 N Engl J Med. 2015 Oct 8;373(15):1479 26444742 BreastNeoplasms diagnosis Breast Self-Examination (...) Early Detection of Cancer Female Humans Mammography Practice Guidelines as Topic 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444744 10.1056/NEJMc1508733 10.1056/NEJMc1508733#SA2
Breast-CancerScreening - Viewpoint of the IARC Working Group. 26444745 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Breast-CancerScreening--Viewpoint of the IARC Working Group. 1479 10.1056/NEJMc1508733 Fitzgerald Stephen P SP eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2015 Jun 11;372(24):2353-8 26039523 N Engl J Med. 2015 Oct 8;373(15):1479 26444742 BreastNeoplasms diagnosis Breast Self (...) -Examination Early Detection of Cancer Female Humans Mammography Practice Guidelines as Topic 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444745 10.1056/NEJMc1508733 10.1056/NEJMc1508733#SA3
Breastcancerscreening and mammography: inform women Prescrire IN ENGLISH - Spotlight ''Breastcancerscreening and mammography: inform women '', 1 July 2015 {1} {1} {1} | | > > > Breastcancerscreening and mammography: inform women Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Breastcancerscreening and mammography: inform women Information (...) must be shared with women to help them decide whether or not to take part in breastcancerscreening. In a series of articles published over the past year, Prescrire updated its analysis of the harm-benefit balance of breastcancerscreening by mammography. In France, it is estimated that, overall, for every 1000 woman aged 50, around 72 women are diagnosed with breastcancer over a period of 20 years. In the 10 years following this diagnosis, around 13 of these women die from breastcancer, and 4
Breast-CancerScreening - Viewpoint of the IARC Working Group. 26039523 2015 06 19 2016 11 25 1533-4406 372 24 2015 Jun 11 The New England journal of medicine N. Engl. J. Med. Breast-cancerscreening--viewpoint of the IARC Working Group. 2353-8 10.1056/NEJMsr1504363 Lauby-Secretan Béatrice B From the International Agency for Research on Cancer, Lyon, France (B.L.-S., C.S., D.L., L.B.-T., V.B., K.S.); and the German Cancer Research Center, Heidelberg, Germany (F.B.). Scoccianti Chiara C Loomis (...) Committees Aged BreastNeoplasms diagnosis diagnostic imaging genetics mortality Breast Self-Examination Cost-Benefit Analysis Early Detection of Cancer methods Female Humans Imaging, Three-Dimensional Mammography Middle Aged Practice Guidelines as Topic Ultrasonography Armstrong Bruce B Anttila Ahti A de Koning Harry J HJ Smith Robert A RA Thomas David B DB Weiderpass Elisabete E Anderson Benjamin O BO Badwe Rajendra A RA da Silva Ronaldo Corrêa Ferreira RC de Bock Geertruida H GH Duffy Stephen W SW
) (currently approved in the EU) 16 and the AMULET Innovality (Fujifilm Europe, Düsseldorf, Germany). 17 Tomosynthesis (3D Mammography) for BreastCancerScreening 2 Patient Group Breastcancer is the most common cancer among Canadian women (excluding non-melanoma skin cancers) and the second leading cause of cancer death in this group. Canadian estimates for 2014 predicted that 24,400 women would be diagnosed with breastcancer (26% of all new cancer cases in women) and 5,000 would die from the disease (...) /en/cancer- information/cancer-type/breast/statistics/?region=bc 19. Lei J, Yang P, Zhang L, Wang Y, Yang K. Diagnostic accuracy of digital breast tomosynthesis versus digital mammography for benign and malignant lesions in breasts: a meta-analysis. Eur Radiol. 2014 Mar;24(3):595-602. 20. Lee CI, Lehman CD. Digital breast tomosynthesis and the challenges of implementing an emerging breastcancerscreening technology into clinical practice. J Am Coll Cardiol. 2013 Dec;10(12):913-7. 21. Canadian
in this group. Canadian estimates for 2014 predicted that 24,400 women would be diagnosed with breastcancer (26% of all new cancer cases in women) and 5,000 would die from the disease (14% of all cancer deaths in women). 18 Challenges with breastcancer are not only its incidence rate but also the lack of proven preventive strategies — early detection and treatment are currently the main approaches. 19 Screening mammography is often credited with significantly reducing the number of deaths from breast (...) , Zhang L, Wang Y, Yang K. Diagnostic accuracy of digital breast tomosynthesis versus digital mammography for benign and malignant lesions in breasts: a meta-analysis. Eur Radiol. 2014 Mar;24(3):595-602. Lee CI, Lehman CD. Digital breast tomosynthesis and the challenges of implementing an emerging breastcancerscreening technology into clinical practice. J Am Coll Cardiol. 2013 Dec;10(12):913-7. Canadian BreastCancer Foundation. Screening by mammography [Internet]. Toronto: The Foundation; 2011
Evaluations 1. Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-effectiveness of alternative strategies for integrating MRI into breastcancerscreening for women at high risk. Br J Cancer [Internet]. 2014 Oct 14 [cited 2015 May 6];111(8):1542-51. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200098 PubMed: PM25137022 Guidelines and Recommendations 2. Institute for Clinical Systems Improvement (ICSI). Health Care Guideline: Diagnosis of BreastDisease 14 th edition [Inetrnet (...) Concurrent versus Sequential Digital Mammography and MRI for BreastCancerScreening in High-Risk Patients Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed
Use of a decision aid including information on overdetection to support informed choice about breastcancerscreening: a randomised controlled trial. Mammography screening can reduce breastcancer mortality. However, most women are unaware that inconsequential disease can also be detected by screening, leading to overdiagnosis and overtreatment. We aimed to investigate whether including information about overdetection of breastcancer in a decision aid would help women aged around 50 years (...) evidence-based explanatory and quantitative information on overdetection, breastcancer mortality reduction, and false positives) or a control decision aid (including information on breastcancer mortality reduction and false positives). Participants and interviewers were masked to group assignment. The primary outcome was informed choice (defined as adequate knowledge and consistency between attitudes and screening intentions), which we assessed by telephone interview about 3 weeks after random
2015LancetControlled trial quality: predicted high